INAB IN8BIO INC

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA.

William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcoming remarks and discuss, “Tackling the Tough Questions in IO for Autoimmunity Disease.” After, he will Chair the session, “State of the IO Market, Investments and Deals Plenary.”

During the afternoon session, at 4:35 PM EDT, Mr. Ho will present on the topic of “Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager,” and provide a corporate overview of IN8bio’s recently announced INB-619, T cell engager program for oncology and autoimmune diseases.

As co-chair and panelist, Mr. Ho expects to discuss the rationale and promise of a gamma-delta T cell engager in addressing autoimmunity, a rapidly emerging frontier for immunotherapies.

Presentation and Panel Details

Co-Chairs' Welcome & Tackling the Tough Questions in IO for Autoimmunity Disease

  • Date/Time: March 25, 2025, at 8:15 AM EDT

Picking Our Horse in the Race for Autoimmunity: The Gamma-Delta T Cell Engager

  • Date/Time: March 25, 2025, at 4:35 PM EDT

For those interested in coordinating a time to meet with the IN8bio during IO360°, please email .

For more information about the event, visit .

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma, and advancing novel gamma-delta T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit .

Investors & Company Contacts:

Glenn Schulman, PharmD, MPH

203.494.7411

IN8bio, Inc.

Patrick McCall

646.933.5603

Media Contact:

Kimberly Ha

KKH Advisors

917.291.5744



EN
18/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conferen...

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025 NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA. William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcom...

 PRESS RELEASE

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and...

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-freeExpanded pipeline with INB-600 platform, featuring novel gamma-delta T Cell engager (TCE) targeting CD19 for potential use in oncology and autoimmune diseasesContinued operational execution with strengthened strategic focus on aligning resources in an effort to drive ...

 PRESS RELEASE

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platfo...

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potencyINB-619, a next generation γδ TCE targeting CD19, eradicates B cells in preclinical models, maintaining depletion over time as γδ T cells expand in response to TCE stimulation γδ TCE targets and expands both Vδ1+ and Vδ2+ T cells, potentially leading to longer lasting immune responses and deeper B cell depletionUnlike traditional TCEs and CAR...

 PRESS RELEASE

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 45th  Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at . About IN8bio IN8bio is a clinical-stage biopharmac...

 PRESS RELEASE

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtu...

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the: H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceDate/Time Tuesday, February 25, 2025, at 11:00 a.m. ET. Webcast Link A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch